Recently, several groups reported that indirectly targeting MYC by the BET bromodomain inhibitor JQ1 exhibited anti-tumor activity in childhood sarcoma, thyroid tumor and endometrial cancer [23–25]. Here, MYC is linked to endometrial cancer.